|
1) Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011; 12: 21-35
|
|
|
|
2) Hosokawa N, Hara T, Kaizuka T, et al. Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. Mol Biol Cell. 2009; 20: 1981-91
|
|
|
|
|
|
3) Jung CH, Jun CB, Ro SH, et al. ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. Mol Biol Cell. 2009; 20: 1992-2003
|
|
|
|
|
|
4) Ganley IG, Lam DH, Wang J, et al. ULK1-ATG12-FIP200 complex mediates mTOR signaling and is essential for autophagy. J Biol Chem. 2009; 284: 12297-305
|
|
|
|
|
|
5) Sancak Y, Peterson TR, Shaul YD, et al. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science. 2008; 320: 1496-501
|
|
|
|
|
|
6) Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004; 14: 1296-302
|
|
|
|
|
|
7) Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol. 2004; 6: 1122-8
|
|
|
|
|
|
8) Huang J, Wu S, Wu CL, et al. Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tissues deficient for the tuberous sclerosis complex tumor suppressors. Cancer Res. 2009; 69: 6107-14
|
|
|
|
|
|
9) Kwiatkowski DJ. Rat and mouse models of tuberous sclerosis. In: Kwiatkowski DJ, et al. editors. Tuberous sclerosis complex. Weinheim: Wiley-Blackwell; 2010. p.117-43
|
|
|
|
|
|
10) Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008; 358: 140-51
|
|
|
|
|
|
11) Davies DM, Johnson SR, Tattersfield AE, et al. Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N Engl J Med. 2008; 358: 200-3
|
|
|
|
|
|
12) Kruger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010; 363: 1801-11
|
|
|
|
|
|
13) Parkhitko A, Myachina F, Morrison TA, et al. Tumorigenesis in tuberous sclerosis complex is autophagy and p62/sequestosome 1 (SQSTM1)-dependent. Proc Natl Acad Sci U S A. 2011; 108: 12455-60
|
|
|
|
|
|
14) Hsu PP, Kang SA, Rameseder J, et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science. 2011; 332: 1317-22
|
|
|
|
|
|
15) Yu Y, Yoon SO, Poulogiannis G, et al. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science. 2011; 332: 1322-6
|
|
|
|
|
|
16) Duvel K, Yecies JL, Menon S, et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell. 2010; 39: 171-83
|
|
|
|
|
|
17) Land SC, Tee AR. Hypoxia-inducible factor 1α is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J Biol Chem. 2007; 282: 20534-43
|
|
|
|
|
|
18) Toschi A, Lee E, Gadir N, et al. Differential dependence of hypoxia-inducible factors 1 and 2 on mTORC1 and mTORC2. J Biol Chem. 2008; 283: 34495-9
|
|
|
|
|
|
19) Fujisaka Y, Yamada Y, Yamamoto N, et al. A phase I clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors. Jpn J Clin Oncol. 2010; 40: 732-8
|
|
|
|
|
20) Tsukamoto T, Shinohara N, Tsuchiya N, et al. Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1. Jpn J Clin Oncol. 2011; 41: 17-24
|
|
|
|
|
|
21) DeYoung MP, Horak P, Sofer A, et al. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev. 2008; 22: 239-51
|
|
|
|
|
|
22) Cam H, Easton JB, High A, et al. mTORC1 signaling under hypoxic condition is controlled by ATM-dependent phosphorylation of HIF-1α. Mol Cell. 2010; 40: 509-20
|
|
|
|
|
|
23) Wolff NC, Vega-Rubin-de-Celis S, Xie XJ, et al. Cell-type-dependent regulation of mTORC1 by REDD1 and the tumor suppressors TSC1/TSC2 and LKB1 in response to hypoxia. Mol Cell Biol. 2011; 31: 1870-84
|
|
|
|
|
|
24) Distefano G, Boca M, Rowe I, et al. Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K1 and 4EBP1. Mol Cell Biol. 2009; 29: 2359-71
|
|
|
|
|
|
25) Dere R, Wilson PD, Sandford RN, et al. Carboxy terminal tail of polycystin-1 regulates localization of TSC2 to repress mTOR. PLoS ONE. 2010; 5: e9239
|
|
|
|
|
|
26) Traykova-Brauch M, Schönig K, Greiner O, et al. An efficient and versatile system for acute and chronic modulation of renal tubular function in transgenic mice. Nat Med. 2008; 14: 979-84
|
|
|
|
|
|
27) Zhou J, Brugarolas J, Parada LF. Loss of Tsc1, but not Pten, in renal tubular cells causes polycystic kidney disease by activating mTORC1. Hum Mol Genet. 2009; 18: 4428-41
|
|
|
|
|
|
28) Tao Y, Kim J, Schrier RW, et al. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol. 2005; 16: 46-51
|
|
|
|
|
|
29) Shillingford JM, Piontek KB, Germino GG, et al. Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J Am Soc Nephrol. 2010; 21: 489-97
|
|
|
|
|
|
30) Serra AL, Poster D, Kistler AD, et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med. 2010; 363: 820-9
|
|
|
|
|
|
31) Walz G, Budde K, Mannaa M, et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2010; 363: 830-40
|
|
|
|
|
|
32) Perico N, Antiga L, Caroli A, et al. Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol. 2010; 21: 1031-40
|
|
|
|
|
|
33) Sakaguchi M, Isono M, Isshiki K, et al. Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice. Biochem Biophys Res Commun. 2006; 340: 296-301
|
|
|
|
|
|
34) Lloberas N, Cruzado JM, Franquesa M, et al. Mammalian taget of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol. 2006; 17: 1395-404
|
|
|
|
|
|
35) Yang Y, Wang J, Qin L, et al. Rapamycin prevents early steps of the development of diabetic nephropathy in rats. Am J Nephrol. 2007; 27: 495-502
|
|
|
|
|
|
36) Mori H, Inoki K, Masutani K, The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential. Biochem Biophys Res Commun. 2009; 384: 471-5
|
|
|
|
|
|
37) Inoki K, Mori H, Wang J, et al. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest. 2011; 121: 2181-96
|
|
|
|
|
|
38) Welsh GI, Hale LJ, Eremina V, et al. Insulin signaling to the glomerular podocyte is critical for normal kidney function. Cell Metab. 2010; 12: 329-40
|
|
|
|
|
|
39) Gödel M, Hartleben B, Herbach N, et al. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest. 2011; 121: 2197-209
|
|
|
|
|
|
40) Vollenbroker B, George B, Wolfgart M, et al. mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocyte. Am J Physiol Renal Physiol. 2009; 296: F418-26
|
|
|
|
|